On Monday 20 June, the European Commission opened a formal antitrust investigation to determine whether Vifor Pharma has restricted competition by illegally disparaging Pharmacosmos, its closest and potentially only competitor in Europe in the intravenous iron therapy market.
Vifor Pharma’s conduct appears to be aimed at “hindering competition in favour of its blockbuster high-dose intravenous iron treatment medicine, Ferinject”, the institution explains.
According to Margrethe...